GE HealthCare Technologies Inc.

ticker: GEHC step: 01 generated: 2026-05-13 source: quick-research

GE HealthCare Technologies Inc. (GEHC) — Business Overview

Business Description

GE HealthCare Technologies (NASDAQ: GEHC) is one of the world's largest medical technology and digital solutions companies, spun off from General Electric in January 2023. The company develops, manufactures, and sells medical imaging equipment, ultrasound systems, patient monitoring solutions, and pharmaceutical diagnostic agents, serving hospitals, imaging centers, and healthcare systems in over 160 countries. With approximately $20B in annual revenue and 51,000+ employees, GEHC is a leading provider of CT scanners, MRI systems, X-ray equipment, PET/SPECT imaging, and AI-powered clinical decision tools, with the FDA's largest portfolio of AI-enabled device authorizations (80+ clearances, targeting 200+ by 2027).

Revenue Model

Revenue is split approximately 65% products and 35% services. Products include imaging equipment (one-time capital sale to hospitals), contrast agents/radiopharmaceuticals (recurring consumables), and increasingly software (transitioning toward subscription). Services include multi-year equipment maintenance contracts, software licenses, and cloud-based digital health solutions. The company is targeting a significant shift toward recurring software and services revenue, with a goal to triple cloud-based solutions and grow digital revenue ~50% by expanding subscription offerings.

Products & Services

• Imaging: CT scanners (Revolution series), MRI systems (Signa series), X-ray, Photonova Spectra photon-counting CT (FDA review pending, 2026 approval expected)
• Ultrasound: Vscan Air (handheld), Venue, Logiq — cardiac, women's health, general imaging
• Advanced Visualization Solutions (AVS): Edison AI platform — FDA-cleared AI tools for radiology workflow, triage, and reporting
• Patient Care Solutions (PCS): Carescape monitoring systems, anesthesia machines, infant care, respiratory care
• Pharmaceutical Diagnostics (PDx): Omnipaque/Visipaque contrast agents, Flyrcado (cardiac PET agent — ~220 weekly doses/week, $500M+ revenue target by 2028), Vizamyl (Alzheimer's amyloid imaging)
• Intelerad (acquired Nov 2025, $2.3B): Cloud-based enterprise imaging software (PACS/VNA) — adds $270M recurring software revenue at 30%+ EBITDA margin

Customer Base & Go-to-Market

Hospital systems, academic medical centers, imaging centers, and specialty clinics worldwide. Government/public healthcare systems (UK NHS, European systems) are significant customers. China historically ~15–20% of revenue. Sold through a direct enterprise sales force (large systems), distributor networks (smaller facilities), and service contracts managed by field engineers. Strong GPO and IDN relationships in the U.S.

Competitive Position

GEHC competes primarily with Siemens Healthineers and Philips in medical imaging, and with Mindray, Canon, and Samsung in ultrasound. GEHC holds leading positions in CT (#1–2 globally), MRI (#2), and X-ray. The AI-enabled device pipeline — largest portfolio of FDA AI clearances in medical imaging — is a key differentiator as hospitals move toward AI-assisted radiology workflows. The NVIDIA partnership (announced GTC 2025) targets autonomous imaging systems (X-ray, ultrasound) with physical AI integration, a multi-year competitive positioning move.

Key Facts

• Founded: 2023 (spun off from GE; predecessor operations date to 1896 with GE's X-ray business)
• Headquarters: Chicago, Illinois
• Employees: ~51,000
• Exchange: NASDAQ
• Sector / Industry: Health Care / Health Care Equipment & Supplies
• Market Cap: ~$18B

ticker: GEHC step: 04 generated: 2026-05-13 source: quick-research

GE HealthCare Technologies Inc. (GEHC) — Financial Snapshot

Income Statement Summary

FY2024 organic revenue growth was modest (~1%) on a reported basis as China weakness and PDx supplier disruption offset growth elsewhere. Adjusted EPS grew 22% to $4.59 in FY2025 (fiscal year reported in early 2026), absorbing $0.43/share in tariff headwinds. Adjusted EBIT margins expanded steadily from ~14.5% (FY2022) to ~17–18% (FY2024–2025).

Cash Flow & Balance Sheet (FY2024)

Key Ratios (approximate)

• P/E: ~15–18x (adjusted) | EV/EBITDA: ~12x | FCF Yield: ~8–9%
• Revenue Growth (FY2024): ~+1% reported (+4% organic ex-China)
• Adjusted EPS (FY2025): $4.59 (+22% YoY, absorbing $0.43 tariff drag)
• Backlog: Record $21.8B (book-to-bill ratio 1.07x at end of 2025)

Growth Profile

GEHC is in the early innings of its post-spin-off strategic transformation — shifting from a GE division focused on hardware to a standalone company emphasizing AI software, cloud services, and recurring revenue. Reported revenue has been flat (~$19.6–19.7B) due to China headwinds and macro-driven capital equipment spending softness, but organic growth ex-China is tracking 4–6%. Adjusted EPS has grown 20%+ YoY as margins expand (Heartbeat lean operating system, mix shift to software/services). The record $21.8B backlog and 1.07x book-to-bill provide solid revenue visibility.

Forward Estimates

• FY2025 Revenue: ~$20.0–20.5B (Q4 FY2025 revenue up 7.1% YoY)
• FY2026 Adjusted EPS Guidance: $4.95–$5.15 (8–12% growth; tariffs guided to "neutral to positive" vs. $0.43 headwind in FY2025)
• FY2026 China Guidance: Anticipated decline — remains a headwind
• Intelerad contribution: ~$270M recurring revenue at 30%+ adjusted EBITDA margin
• Analyst consensus: 14 of 20 analysts Buy/Outperform; median price target $95, implying ~29% upside